A 19-year-old pregnant woman, who recently immigrated to the United States from West Africa presented to the hospital with complaints of nausea, vomiting, recent diarrhea, and lower abdominal pain. She was a 34.4-week primapara and reported that her symptoms began several days before admission and were increasing in severity. The patient reported no significant past medical history. She had not taken malaria prophylaxis, as directed by her physicians in Liberia.
demonstrated uterine contractions, without significant decelerations. Laboratory findings showed elevated bilirubin and liver enzymes, a significant pancytopenia, with a leukopenia (1940 WBCs/cumm) and left-shifted hematopoiesis (34% bands), thrombocytopenia (17,000 platelets/cumm), and a diminished hemoglobin and hematocrit (8.4 g/dl and 24.1%, respectively). A peripheral smear confirmed the pancytopenia, showed schistocytes, and disclosed Plasmodium-infected erythrocytes. The parasite was promptly determined to be Plasmodium falciparum and the parasitemia was determined to be 3%. The patient was treated with a combination of quinidine and clindamycin (quinidine gluconate 500 mg intravenous (IV) loading dose, followed by a continuous infusion at 1.0 to 1.2 mg/min; clindamycin 900 mg IV every 8 hours), because she had immigrated from a region where chloroquine-resistant P. falciparum strains have been reported. The antiplasmodial therapy resulted in a rapid decrease in peripheral parasitemia and subsequent elimination of plasmodia from the circulation. The patient was concurrently stabilized by packed red blood cell and platelet transfusions. She underwent cesarean section delivery secondary to nonreassuring fetal heart tones, with late decelerations and failure of the delivery to progress. At the time of delivery, the patient had received 22.5 hours of quinidine/clindamycin, with almost complete clearance of plasmodia from the peripheral circulation; extremely rare parasites were detected only after an exhaustive search. The infant was delivered without complications and did not develop malaria.
Histopathologic examination of the placenta demonstrated extensive sequestration of P. falciparum-infected erythrocytes in the maternal sinuses, with a local parasitemia of 70% to 80% ( Figure  1 ). Other histopathologic findings, which have been associated with malaric placentas were also present, including fibrin deposition and abundant malarial pigment within placental histiocytes. Rare plasmodia were detected in the fetal circulation of the placenta. The child was treated and did not develop malaria.
Several maternal and neonatal peripheral blood smears, obtained during the postpartum period, were negative for P. falciparum. Unfortunately, the mother developed several complications, which included aspiration pneumonia, severe adult respiratory distress syndrome, and pulmonary emboli. Right heart failure and disseminated intravascular coagulation ensued and she expired despite advanced cardiac and pulmonary life-support measures. Consent for a postmortem examination could not be obtained.
The persistence of Plasmodium falciparum in the placenta after apparently adequate therapy with quinine has been described. 1 We describe this phenomenon in the placenta of a 19 -year -old woman with falciparum malaria, who was treated with a combination of quinidine and clindamycin. Although this therapy was effective and diminished her peripheral blood parasitemia from 3% at presentation to almost undetectable at the time of delivery, vast numbers of P. falciparuminfected erythrocytes were present in the maternal sinusoids of the placenta. This sequestration of infected erythrocytes produced a local parasitemia in the placenta of 70% to 80%. Additionally, rare Plasmodium -infected erythrocytes were also seen in the fetal blood of the placenta. We review malaria in pregnancy, parasitic involvement of the placenta and emphasize that Plasmodium -infected erythrocytes may persist in the placenta even after clearance of parasites from the peripheral blood. 
Clinical Perinatal/Neonatal Case Presentations
P. falciparum infection is the most devastating and rapidly fatal type of malaria.
2,3
Falciparum malaria causes 1 to 2 million deaths annually, many of whom are children. 4 The high fatality rate is secondary to a combination of the hemolytic anemia, hypoglycemia, and lactic acidosis, caused by the high rate of parasite replication, and the significant ischemic sequelae secondary to parasite/ endothelial cell adherence.
Pregnant women who contract falciparum malaria are at increased risk for more severe disease compared to nonpregnant women. 3, 5 Furthermore, of pregnant women who contract falciparum malaria, primagravida women are at higher risk for severe disease compared with multiparous pregnant women. 6 ± 8 Complications during pregnancy secondary to falciparum malaria include premature labor, spontaneous abortion, adult respiratory distress syndrome (ARDS), and the delivery of infants that are small for gestational age.
3,9 ± 11
Parasitic involvement of the placenta also impedes passive antibody transfer to the fetus. 12 Even after delivery, women who have contracted falciparum malaria during pregnancy are at increased risk for the development of ARDS, possibly secondary to the increase blood volume associated with delivery. 3, 9, 10 The placenta is usually involved in patients with falciparum malaria; microscopic examination of the placenta are just as sensitive, and possibly more sensitive than concurrently obtained thick blood preparations for the diagnosis of malaria in patients from endemic areas. 13, 14 During pregnancy, Plasmodium-infected erythrocytes are sequestered in the placenta through cytoadherent mechanisms that are probably different from those in the peripheral circulation. In the peripheral circulation, P. falciparum-infected erythrocytes produce cytoplasmic protrusions, which contain parasite-derived membrane proteins, which mediate adherence to the endothelial ligand glycophorin A. 3, 5 In the maternal circulation of the placenta, P. falciparum-infected erythrocytes adhere to a variety of ligands. Cytoadherence in the placenta may involve intercellular adhesion molecule-1 (ICAM-1) and chondroitin sulfate. 7, 15, 16 More recently, hyaluronic acid has been shown to be important for placental parasitic adherence. 17 The histopathologic examination of the placenta demonstrates the degree of local parasitemia, which may explain the clinical findings of placental insufficiency. Although the preponderance of parasitized erythrocytes reside in the maternal sinusoids (Figure 1 ), histopathologic examination also affords an opportunity to identify parasitized erythrocytes in the fetal circulation (Figure 2 ). 14, 18, 19 These residual parasitized erythrocytes that are sequestered in the placenta occupy space and physically displace noninfected, oxygen-carrying erythrocytes. Other changes that may be identified include increased fibrin deposition and malarial or hemozoin pigment in the placental histiocytes. 14, 18 Ultrastructural examination may disclose a thickened basal lamina and syncytiotrophoblastic injury. 14 We and others have shown that P. falciparum-infected erythrocytes may persist in placenta despite apparently adequate therapy, as judged by the clearance of peripheral blood parasitemia. 1 This persistence of parasites in the placenta after therapy is concerning and suggests that further study, with respect to the efficacy of these drugs is required. Mefloquine, another antiplasmodial drug is promising as an agent that may be useful during pregnancy. In sub-Saharan Africa, mefloquine has been shown to be more efficacious than chloroquine in decreasing persistent and breakthrough infections, as well as diminishing the risk of peripheral, placental, and umbilical cord parasitemia at the time of delivery. 6 Others, however, suggest that both mefloquine and quinine have high failure rates in pregnant women with primary and recrudescent P. falciparum infections and promote the use of Artemisinin-based treatments. 20 If possible, avoidance of malariaendemic areas by pregnant women and children is recommended. For women who develop falciparum malaria during pregnancy, monitoring for placental insufficiency would be prudent, even if the patient demonstrates a response to antiplasmodial therapy. 
